

Establishment Name	Boehringer Ingelheim Animal Health USA Inc.
USDA Vet Biologics Establishment Number	124
Product Code	2775.02
True Name	Mycoplasma Hyopneumoniae Bacterin
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Ingelvae Mycoftes - Agritech Enterprise Safa Bhd Ingelvae Mycoftes - Bochringer Ingelheim Animal Health Australia Pty. Ltd. Ingelvae Mycoftes - Bochringer Ingelheim Animal Health Australia Pty. Ltd. Ingelvae Mycoftes - Bochringer Ingelheim Animal Health Korea, Ltd. Ingelvae Mycoftes - Bochringer Ingelheim Animal Health Korea, Ltd. Ingelvae Mycoftes - Bochringer Ingelheim Animal Health Netzio Ingelvae Mycoftes - Bochringer Ingelheim Animal Health Africa (Pty) Ltd (Edms) Bpk Ingelvae Mycoftes - Bochringer Ingelheim Animal Health do Brasi Ltda Ingelvae Mycoftes - Bochringer Ingelheim Animal Health do Brasi Ltda Ingelvae Mycoftes - Bochringer Ingelheim Animal Health do Brasi Ltda Ingelvae Mycoftes - Bochringer Ingelheim Animal Health do Brasi Ltda Ingelvae Mycoftes - Bochringer Ingelheim Animal Health do Brasi Ingelvae Mycoftes - Bochringer Ingelheim Anima do Brasi Ingelvae Mycoftes - Bochringer Ingelheim SA. Ingelvae Mycoftes - Bochring
Date of Compilation Summary	December 02, 2020

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

Study Type	Efficacy				
Pertaining to	Mycoplasma Hyponeumoniae				
Study Purpose	Demonstration of the minimum efficacious dose				
Product Administration	Administration of one dose intramuscularly				
Study Animals	Pigs 3 weeks of age, divided into 20 vaccinates and 20 control pigs				
Challenge Description	Challenged with Mycoplasma hyopneumoniae 28 days post				
	vaccination				
Interval observed after	Pigs were observed for 27 days post-challenge for clinical signs of				
challenge	Mycoplasma hyopneumoniae infection and then tissues were				
	examined for determination of lung lesions.				
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.				
USDA Approval Date	August 10, 2006				

Study Type	Efficacy				
Pertaining to	Mycoplasma Hyponeumoniae				
Study Purpose	Demonstration of a 26 week Duration of Immunity				
Product Administration	Administration of one dose intramuscularly				
Study Animals	Pigs approximately 3 weeks of age, divided into 20 vaccinates				
	and 20 controls				
Challenge Description	Challenged with Mycoplasma hyopneumoniae 184 days post				
	vaccination				
Interval observed after	Pigs were observed for 33 days post-challenge for clinical signs				
challenge	of <i>Mycoplasma hyopneumoniae</i> infection and then tissues were				
chancinge	examined for lung lesions consistent with <i>Mycoplasma</i>				
	hyopneumoniae infection.				
	V 1				
Results	Study data were evaluated by USDA-APHIS prior to product				
	licensure and met regulatory standards for acceptance at the time				
	of submission. No data are published because this study was				
	submitted to USDA-APHIS prior to January 1, 2007, and APHIS				
	only requires publication of data submitted after that date.				
USDA Approval Date	August 7, 2006				

Study Type	Safety					
Pertaining to	All					
Study Purpose						
Product Administration	To demonstrate safety under field conditions					
Study Animals	Single intramuscular administration					
Study Annais	1355 pigs at 10 - 30 days of age, (≥200 pigs from each of three different geographical locations were vaccinated, and a similar					
	number at each site were not vaccinated for comparison)					
Challenge Description	Not applicable					
Interval observed after	Pigs were observed immediately following vaccination and then					
challenge	for 14 days following vaccination. No challenge was conducted.					
Results	Observations of Vaccinated Pigs:					
	Clinical Observation ^a	MO Site N=244	NE Site N=229	IN Site N=207		
	None ^b	241	210	193		
	Poor Condition [°]	0	15	0		
	Dead ^d	3	2	3		
	Scours	0	1	10		
	Lame	0	1	0		
	Swollen Joint(s)	2	0	0		
	Cough	0	0	1		
	Skin Abnormalities ^e	0	1	1		
	^a Pigs may have exhibited mor ^b For an observation of "None observations for the entire 14 ^c Observations of "Poor Cond small thin, small, gaunt, gaun ^d Observation of "Dead" inclu ^e Observation of "Skin Abnor and skin spots	" a pig had days of the ition" includ t weak, and ded: Dead,	to be witho study. ded: thin sta thin. Died, and E	ut clinical urve, Euthanized.		

	Observations of Control Pigs:					
	Clinical Observation ^a	MO Site N=241	NE Site N=228	IN Site N=206		
	None ^b	237	209	195	1	
	Poor Condition ^c	0	13	0		
	Dead ^d	4	2	1		
	Scours	0	0	9		
	Lame ^e	0	3	1		
	Swollen Joint(s)	2	0	0		
	Hernia ^f	0	2	0		
	 ^a Pigs may have exhibited more than one clinical observation. ^b For an observation of "None" a pig had to be without clinical observations for the entire 14 days of the study. ^c Observations of "Poor Condition" included: thin, gaunt, gaunt/weak, and gaunt-purple ears. ^d Observation of "Dead" included: dead, died, and euthanized. ^e Observation of "Lame" included: lame, sore right front foot, shoulder ^f Observation of "Hernia" included: hernia and surgery. 					
USDA Approval Date	April 5, 2006					